Phase 1/2 trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT...

Date 29 September 2019
Event ESMO 2019 Congress
Session Poster Display session 2
Topics Cervical Cancer
Presenter Ignace Vergote
Citation Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250
Authors I.B. Vergote1, N. Concin2, M.R. Mirza3, A. Malmberg4, L. Eaton5, L. Nicacio6, D. Lorusso7, I. Soumaoro5, B.J. Monk8, D.M. O'Malley9
  • 1Gynaecology, University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE
  • 2Gynaecology, Belgium and Luxembourg Gynaecological Oncology Group, University of Leuven, Leuven Cancer Institute, 3000 - Leuven/BE
  • 3Department Of Oncology, Copenhagen University Hospital - Rigshospitalet, 2100 - Copenhagen/DK
  • 4Oncology, Genmab, 1560 - Copenhagen/DK
  • 5Oncology, Genmab US, Inc., 08540 - Princeton/US
  • 6Oncology, Seattle Genetics, Inc, 98021 - Bothell/US
  • 7Gynecologic Oncology, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 8Division Of Gynecologic Oncology, St Joseph’s Hospital and Medical Center, 85724-5024 - Phoenix/US
  • 9Gynecologic Oncology, The Ohio State University Comprehensive Cancer Center, 43210 - Columbus/US

Abstract

Background

The current standard-of-care first-line therapy for patients (pts) with recurrent/metastatic cervical cancer (r/mCC) is paclitaxel/platinum ± bevacizumab (BEV). However, approximately 50% of pts who are eligible to receive this regimen do not respond to the treatment. Tissue factor (TF) is highly expressed in cervical cancer and is associated with poor prognosis. Tisotumab vedotin (TV) is an investigational first-in-class antibody-drug conjugate comprising a fully human monoclonal antibody targeting TF conjugated to the microtubule-disrupting agent monomethyl auristatin E via a protease-cleavable linker. Single-agent TV demonstrated encouraging antitumor activity (independent review committee–assessed confirmed ORR, 22%; median DOR, 6.0 mo) and a manageable safety profile in pts with previously treated r/mCC. innovaTV 205/ENGOT-cx8 (NCT03786081; GOG-3024) is a global, multicenter, open-label, phase 1/2 trial evaluating the safety and antitumor activity of TV in combination with BEV, pembrolizumab (PEM), or carboplatin (CBP) in pts with untreated and previously treated r/mCC. Results from the innovaTV 205 study will inform the further clinical development of TV in cervical cancer.

Trial design

Approximately 140 adult pts with recurrent or stage IVB squamous, adenosquamous, or adenocarcinoma of the cervix; measurable disease; and ECOG PS 0-1 will be enrolled. The phase 1 portion of the study will consist of 3 dose escalation cohorts for identification of the recommended phase 2 dose (RP2D) of TV with BEV, PEM, or CBP. The phase 2 portion will include 3 expansion cohorts. In the dose escalation cohorts, previously treated pts will receive escalating doses of TV (IV 1Q3W) in combination with escalating doses of BEV (IV 1Q3W), a fixed dose of PEM (IV 1Q3W), or a fixed dose of CBP (IV 1Q3W). In the expansion cohorts, pts who have not received prior systemic therapy for r/mCC will receive 1) TV RP2D + PEM or 2) TV RP2D + CBP; pts who received 1-2 prior treatments for r/mCC will receive TV RP2D + PEM. Additional cohorts might be added. The primary endpoint of phase 2 is ORR (RECIST v1.1). Secondary endpoints include DOR, time to response, PFS, OS, and safety.

Clinical trial identification

NCT03786081; GOG-3024.

Editorial acknowledgement

ApotheCom, San Francisco, CA, USA.

Legal entity responsible for the study

Genmab.

Funding

Genmab.

Disclosure

I.B. Vergote: Advisory / Consultancy: Advaxis; Advisory / Consultancy: Eisai; Advisory / Consultancy: MSD Belgium; Advisory / Consultancy: Roche NV; Advisory / Consultancy, Research grant / Funding (self): Genmab; Advisory / Consultancy: F. Hoffmann-La Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: PharmaMar; Advisory / Consultancy: Millennium; Advisory / Consultancy: Clovis; Advisory / Consultancy, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro; Advisory / Consultancy, Research grant / Funding (self): Oncoinvent; Advisory / Consultancy: Immunogen; Research grant / Funding (self): Amgen; Research grant / Funding (self), Travel / Accommodation / Expenses: Roche; Research grant / Funding (self): Stichting Tegen Kanker; Travel / Accommodation / Expenses: Takeda. N. Concin: Advisory / Consultancy: Seattle Genetics; Advisory / Consultancy: AstraZeneca; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Genmab; Travel / Accommodation / Expenses: Amgen. M.R. Mirza: Honoraria (self), Research grant / Funding (institution): AstraZeneca; Honoraria (self): Biocad; Honoraria (self), Research grant / Funding (institution): Clovis; Honoraria (self): Geneos; Honoraria (self): Genmab; Honoraria (self): Karyopharm; Honoraria (self): Merck; Honoraria (self): Oncology Venture; Honoraria (self), Research grant / Funding (institution): Pfizer; Honoraria (self): Seattle Genetics; Honoraria (self): Sera Prognostics; Honoraria (self): Sotio; Honoraria (self), Research grant / Funding (institution): Tesaro; Honoraria (self): ZaiLab; Research grant / Funding (institution): Boehringer Ingelheim. A. Malmberg: Full / Part-time employment: Genmab. L. Eaton: Full / Part-time employment: Genmab. L. Nicacio: Full / Part-time employment: Seattle Genetics. D. Lorusso: Advisory / Consultancy, Research grant / Funding (institution): Tesaro; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy, Research grant / Funding (institution): Clovis; Advisory / Consultancy: Merrimack. I. Soumaoro: Full / Part-time employment: Genmab. B.J. Monk: Honoraria (self), Advisory / Consultancy, Oncomed (honoraria/consultant): AbbVie; Honoraria (institution), Advisory / Consultancy, Oncoquest (honoraria/consultant): Advaxis; Honoraria (self), Advisory / Consultancy, Oncosec (honoraria/consultant): Agenus; Honoraria (self), Advisory / Consultancy, Perthera (honoraria/consultant): Amgen; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Pfizer (honoraria/consultant): AstraZeneca; Honoraria (self), Advisory / Consultancy, Precision Oncology (honoraria/consultant): ChemoCare; Honoraria (self), Advisory / Consultancy, Puma (honoraria/consultant): ChemoID; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Roche/Genentech (honoraria/speaker/consultant): Clovis; Honoraria (self), Advisory / Consultancy, Samumed (honoraria/consultant): Conjupro; Honoraria (self), Advisory / Consultancy, Takeda (honoraria/consultant): Eisai; Honoraria (self), Advisory / Consultancy, Vesaro (honoraria/speaker/consultant): Geistlich; Honoraria (self), Advisory / Consultancy, VBL (honoraria/consultant): Genmab; Honoraria (self), Advisory / Consultancy: ImmunoGen; Honoraria (self), Advisory / Consultancy: Immunomedics; Honoraria (self), Advisory / Consultancy: Incyte; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Janssen/J&J; Honoraria (self), Advisory / Consultancy: Mateon (formerly Oxigene); Honoraria (self), Advisory / Consultancy: Merck; Advisory / Consultancy: Myriad; Honoraria (self), Advisory / Consultancy: Nucana. D.M. O’Malley: Advisory / Consultancy, Research grant / Funding (institution), Officer / Board of Directors, Ergomed Clinical Research (research support - institution): Clovis; Advisory / Consultancy, Research grant / Funding (institution), Exelixis (research support - institution): AstraZeneca; Advisory / Consultancy, Henry Jackson Foundation (research support - institution): Janssen; Advisory / Consultancy, Research grant / Funding (institution), Genentech (research support - institution): Gynecologic Oncology Group; Advisory / Consultancy, GSK (research support - institution): Myriad; Advisory / Consultancy, Research grant / Funding (institution), INC Research (research support - institution): Tesaro; Advisory / Consultancy, inVentiv Health Clinical (research support - institution): Novocure; Advisory / Consultancy, Janssen Research and Development (research support - institution): Translational Genomics/Cordgenics; Officer / Board of Directors, Ludwig Institute for Cancer Research (research support - institution): Novocure; Officer / Board of Directors, Novartis (research support - institution): Amgen; Research grant / Funding (institution), Officer / Board of Directors, PharmaMar (research support - institution): Immunogen; Advisory / Consultancy, Research grant / Funding (institution), Pfizer (research support - institution): AbbVie; Advisory / Consultancy, PRA International (research support - institution): Health Analytics; Advisory / Consultancy, Regeneron (research support - institution): Ambry; Research grant / Funding (institution), Sanofi (research support - institution): Advaxis; Research grant / Funding (institution), Serono (research support - institution): Agenus; Research grant / Funding (institution), Stemcentrx (research support - institution): Ajinomoto; Research grant / Funding (institution), Tracon (research support - institution): Array BioPharma; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Eisai.